Alimentary Health is the winner of the 2015 US-Ireland research and Innovation award in the SME category for its PrecisionBiotic® culture
In recognition of its outstanding work in the development and commercialisation of precision probiotics for digestive disorders, Alimentary Health has been awarded winner of the prestigious 2015 US-Ireland Research Innovation Award in the SME category. Developed by the American Chamber of Commerce Ireland and the Royal Irish Academy, these awards acclaim exemplary ideas, originating in Ireland, which have made a social and economic impact through research and innovation.
Alimentary Health was recognised specifically for its global innovation in developing 35624™ a patented PrecisionBiotic® supplement, available over-the-counter. Today the 35624™ is liberating millions of people in the US, Canada, UK and Ireland from the misery and debilitating effects of digestive dysfunction. Marketed in Ireland and the UK by Alimentary Health as Alflorex®, and by Procter & Gamble in North America as Align®, The 35624™ culture is the ‘No. 1 Gastroenterologist recommended probiotic strain in the US’. In addition Align has been specifically indicated in Canada to treat the symptoms of Irritable Bowel Syndrome. Furthermore, this year Alflorex® was awarded Best Irish Pharmacy Product at the Irish Pharmacy Awards after only 10 months on the market.
CEO of Alimentary Health, Dr Barry Kiely said:
“It is a tremendous honour for Alimentary Health to have been selected as the winner of such a prestigious award in scientific innovation. Scientific research is at the very heart of our company and the key the driver in our capacity to develop ground breaking healthcare products. Our continuous commitment to research and innovation has enabled Alimentary Health to create a rich pipeline of exciting new products which we plan to bring to a global market over the next three years”.